Qiang Wu

Publications (3)5.97 Total impact

• Article: Aurora B kinase is required for cytokinesis through effecting spindle structure.

  Qiang Wu, Wei Zhang, Tianhao Mu, Tianqiang Song, Dengwen Li
  [show abstract] [hide abstract]
  ABSTRACT: The spindle, composed of microtubules and associated proteins, serves as major machinery for cell division. Aurora B is a chromosome passenger protein that has important functions in mitosis. Its dynamic distribution at mitosis goes along with spindle structure and dynamics. We used the siRNA technique to knockdown protein expression and immunofluorescence technique to follow Aurora B during mitosis. Aurora B regulates microtubule plus ends as mitosis progresses, including both kinetochore and polar microtubules. Interactions between Aurora B and polar microtubule plus ends lead to failure in cytokinesis and abnormal midbody structure. We think Aurora B may not only play a role as kinase, but regulate microtubule plus ends.
  Cell Biology International 05/2013; 37(5):436-42. · 1.48 Impact Factor
• Article: A single center experience of sorafenib in advanced hepatocellular carcinoma patients: evaluation of prognostic factors.

  Tianqiang Song, Wei Zhang, Qiang Wu, Dalu Kong, Weiwei Ma
  [show abstract] [hide abstract]
  ABSTRACT: Sorafenib is the only effective drug for advanced hepatocellular carcinoma (HCC), but few data predictive of its effectiveness are available. To address this issue we analyzed the relationship between risk factors associated with sorafenib treatment and overall survival (OS). Forty patients with advanced HCC were treated with sorafenib. OS was the primary endpoint and tumor response was evaluated using the Response Evaluation Criteria in Solid Tumors. Demographics, and the efficacy and adverse effects of sorafenib were analyzed. Univariate and multivariate analysis were carried out to identify risk factors for OS. The side-effects of sorafenib were summarized, and published data related to sorafenib in patients with HCC were reviewed. The median OS was 12.7 months. A partial response was achieved in five patients and stable disease was achieved in 24 patients, with a disease-stabilization rate of 60%. Hand-foot syndrome, hypertension, diarrhea, and fatigue were common adverse effects. Univariate analysis showed that tumor/lymph node/metastasis staging, Barcelona Clinic Liver Cancer staging, distant metastasis, ascites, and portal thrombosis were risk factors for OS. Multivariate analysis demonstrated that the presence of distant metastasis and ascites predicted poorer OS, and the presence of adverse effects predicted better OS. Presence of adverse effects can be used for monitoring the efficacy of sorafenib that has not been reported in previous studies. Sorafenib demonstrated good efficacy and acceptable tolerability in treating an advanced HCC patient population, with or without prior treatment. The presence of ascites or distant metastasis predicted poorer OS, and the presence of adverse effects predicted improved OS.
  European journal of gastroenterology & hepatology 09/2011; 23(12):1233-8. · 1.66 Impact Factor
• Article: Treatment of colorectal cancer with unresectable synchronous liver-only metastases with combined therapeutic modalities.

  Yunlong Cui, Huikai Li, Qiang Wu, Ti Zhang, Dalu Kong, Tianqiang Song, Tao Ru, Ping Chen, Qiang Li
  [show abstract] [hide abstract]
  ABSTRACT: Resection + radiofrequency ablation (RFA) + hepatic artery infusion (HAI) + systemic chemotherapy for patients with unresectable synchronous liver-only metastases from colorectal cancer was rarely used previously. We compared the outcomes of 42 patients underwent resection + RFA + HAI + systemic chemotherapy (RRHS) with that of 43 patients underwent resection + RFA + systemic chemotherapy (RRS). The overall survival, the survival free of hepatic recurrence and the median survival in the RRHS group were all significantly higher than those in RRS group at 4 years. While the rates of adverse effects were similar in the two groups. For patients with unresectable synchronous liver-only metastases from colorectal cancer, RRHS not only decreases but also postpones hepatic recurrence and therefore improves overall survival at 4 years, as compared with RRS.
  Journal of Gastrointestinal Surgery 10/2010; 15(2):285-93. · 2.83 Impact Factor